ATE492559T1 - Makrocyclische peptide als hepatitis-c-virus- hemmer - Google Patents

Makrocyclische peptide als hepatitis-c-virus- hemmer

Info

Publication number
ATE492559T1
ATE492559T1 AT07864430T AT07864430T ATE492559T1 AT E492559 T1 ATE492559 T1 AT E492559T1 AT 07864430 T AT07864430 T AT 07864430T AT 07864430 T AT07864430 T AT 07864430T AT E492559 T1 ATE492559 T1 AT E492559T1
Authority
AT
Austria
Prior art keywords
hepatitis
macrocyclic peptides
virus inhibitors
compounds
disclosed
Prior art date
Application number
AT07864430T
Other languages
German (de)
English (en)
Inventor
Alan Xiangdong Wang
Barbara Zhizhen Zheng
Andrea Stanley D
Nicholas A Meanwell
Paul Michael Scola
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE492559T1 publication Critical patent/ATE492559T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07864430T 2006-11-16 2007-11-15 Makrocyclische peptide als hepatitis-c-virus- hemmer ATE492559T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86612006P 2006-11-16 2006-11-16
US11/939,753 US8003604B2 (en) 2006-11-16 2007-11-14 Hepatitis C virus inhibitors
PCT/US2007/084777 WO2008064057A1 (en) 2006-11-16 2007-11-15 Macrocyclic peptides as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
ATE492559T1 true ATE492559T1 (de) 2011-01-15

Family

ID=39251294

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07864430T ATE492559T1 (de) 2006-11-16 2007-11-15 Makrocyclische peptide als hepatitis-c-virus- hemmer

Country Status (7)

Country Link
US (1) US8003604B2 (enExample)
EP (1) EP2089020B1 (enExample)
JP (1) JP5241728B2 (enExample)
AT (1) ATE492559T1 (enExample)
DE (1) DE602007011493D1 (enExample)
NO (1) NO20091846L (enExample)
WO (1) WO2008064057A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
US20120095211A1 (en) * 2010-09-22 2012-04-19 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
JP6774403B2 (ja) 2014-06-12 2020-10-21 アロサイト ファーマスーティカルズ アーゲー 小分子ｌｆａ−１阻害薬

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ES2315568T3 (es) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
AU2003248535A1 (en) 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771050A (zh) 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
DE602004029866D1 (de) 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
RS20050741A (sr) 2003-04-02 2007-06-04 Boehringer Ingelheim International Gmbh., Farmaceutske kompozicije za inhibitore virusne proteaze hepatitisa c
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
WO2004093798A2 (en) 2003-04-18 2004-11-04 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
EP1673385B1 (en) 2003-09-22 2011-03-02 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
CN1894274A (zh) * 2003-09-26 2007-01-10 先灵公司 丙肝病毒ns3丝氨酸蛋白酶的大环抑制剂
NZ546663A (en) 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MXPA06005683A (es) 2003-11-20 2006-12-14 Schering Corp Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20060118532A (ko) * 2003-12-11 2006-11-23 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ３／ｎｓ４ａ 세린 프로테아제의억제제
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
EP1749007A2 (en) 2004-03-30 2007-02-07 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
JP4914348B2 (ja) 2004-06-28 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
KR20070034119A (ko) 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
US7375218B2 (en) 2004-09-17 2008-05-20 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic HCV protease inhibitors
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103172697A (zh) 2005-03-08 2013-06-26 贝林格尔.英格海姆国际有限公司 制备大环化合物的方法
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US7772178B2 (en) 2005-06-02 2010-08-10 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
JP2008545748A (ja) 2005-06-02 2008-12-18 シェーリング コーポレイション Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
US20080200497A1 (en) 2005-07-20 2008-08-21 Bailey Murray D Hepatitis C Inhibitor Peptide Analogs
EP2305696A3 (en) 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
WO2007014922A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
EP1910347A2 (en) 2005-07-29 2008-04-16 Medivir Ab Macrocylic inhibitors of hepatitis c virus
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
BRPI0614637A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos do vìrus da hepatite c
AR055105A1 (es) 2005-07-29 2007-08-08 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c
EP1919904B1 (en) 2005-07-29 2014-01-08 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
ATE496042T1 (de) 2005-07-29 2011-02-15 Tibotec Pharm Ltd Makrocyclische inhibitoren des hepatitis-c-virus
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2007016476A2 (en) 2005-08-01 2007-02-08 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007082131A1 (en) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
JP2009528353A (ja) 2006-03-03 2009-08-06 シェーリング コーポレイション Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors

Also Published As

Publication number Publication date
WO2008064057A1 (en) 2008-05-29
JP2010510967A (ja) 2010-04-08
EP2089020A1 (en) 2009-08-19
JP5241728B2 (ja) 2013-07-17
DE602007011493D1 (de) 2011-02-03
EP2089020B1 (en) 2010-12-22
US8003604B2 (en) 2011-08-23
NO20091846L (no) 2009-06-08
US20080159982A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
ATE492558T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
DE602007011493D1 (de) Makrocyclische peptide als hepatitis-c-virus-hemmer
ATE532794T1 (de) Tripeptide als hemmer des hepatitis-c-virus
EA200900697A1 (ru) Ингибиторы вируса гепатита с
EA200900676A1 (ru) Ингибиторы вируса гепатита с
EA201190013A1 (ru) Ингибиторы ns5a вгс
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
WO2008008776A3 (en) Hepatitis c virus inhibitors
EA200900297A1 (ru) Ингибиторы вируса гепатита с
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
NO20091704L (no) Inhibitorer av hepatitt C virus
NO20091707L (no) Inhibitorer av hepatitt C virus
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
ATE474827T1 (de) Hcv-replikationshemmer
JO2593B1 (en) Protease inhibitors NS3 hepatitis C HCV virus
EA201190007A1 (ru) Ингибиторы ns5a вгс
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA201101240A1 (ru) Ингибиторы вируса гепатита с
NO20091706L (no) Inhibitorer av hepatitt C virus
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
EA201370078A1 (ru) Ингибиторы вируса гепатита с
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties